Electrolyte Blood Press.  2015 Jun;13(1):22-29. 10.5049/EBP.2015.13.1.22.

Abdominal Obesity and Mortality in Continuous Ambulatory Peritoneal Dialysis Patients

• Jin H
• Shin JY
• Lee SH
• Song JH
• Kim MJ
• Lee SW

• KMID: 2052339
• DOI: http://doi.org/10.5049/EBP.2015.13.1.22

Abstract

BACKGROUND
The relationship between abdominal obesity (AO) and mortality in peritoneal dialysis (PD) patients is controversial.
METHODS
The prevalence of AO in 84 PD patients was assessed in a cross-section manner and followed up for 9 years at a single center. AO was defined as a waist circumference (WC) of more than 90 cm in males or more than 80 cm in females. The patients were classified as either with AO(AO group) or without AO(nAO group).
RESULTS
The AO group was older, contained more diabetics, more females, and had higher Charlson comorbidity index (aCCI) scores, BMI, and triglyceride and lower serum creatinine than the non-AO subjects. The follow-up duration was 53.2+/-34.4 months. At the end of the follow-up, eighteen patients (21.4%) were dead; 9 died of cardiovascular causes. The five year survival rate was 40.8%. Kaplan-Meier analysis revealed that both all-cause and cardiovascular-cause mortalities were similar in the AO and nAO groups. Multivariate analysis revealed the presence of AO not to be an independent risk factor of all-cause and cardiovascular-cause mortality.
CONCLUSION
AO itself might not be a risk factor for mortality in PD patients. Nevertheless, further prospective studies with a large number of patients will be needed to prove this.

Keyword

Abdominal obesity; Continuous ambulatory peritoneal dialysis; Mortality; Risk factors; Chronic kidney failure

MeSH Terms

Comorbidity
Creatinine
Female
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Kidney Failure, Chronic
Male
Mortality*
Multivariate Analysis
Obesity, Abdominal*
Peritoneal Dialysis
Peritoneal Dialysis, Continuous Ambulatory*
Prevalence
Risk Factors
Survival Rate
Triglycerides
Waist Circumference
Creatinine

Figure

• 

  Fig. 1 Kaplan-Meier curve for (A) All-cause and (B) Cardiovascular-cause mortalities according to abdominal obesity.

Reference

1. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case control study. Lancet. 2004; 364:937–952. PMID: 15364185.

2. Kramer HJ, Saranathan A, Luke A, et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol. 2006; 17:1453–1459. PMID: 16597682.

3. Zoccali C. The obesity epidemics in ESRD: from wasting to waist? Nephrol Dial Transplant. 2009; 24:376–380. PMID: 18952700.

4. Li PK, Kwan BC, Szeto CC, Ko GT. Metabolic syndrome in peritoneal dialysis patients. NDT Plus. 2008; 1:206–214. PMID: 25983884.

5. Krediet RT, Balafa O. Cardiovascular risk in the peritoneal dialysis patient. Nat Rev Nephrol. 2010; 6:451–460. PMID: 20567248.

6. Krediet RT, Boeschoten EW, Zuyderhoudt FM, Arisz L. The relationship between peritoneal glucose absorption and body fluid loss by ultrafiltration during continuous ambulatory peritoneal dialysis. Clin Nephrol. 1987; 27:51–55. PMID: 3829478.

7. Ku YM, Kim YS, Yoon SA, et al. Comparison of prevalence of visceral obesity between hemodialysis and peritoneal dialysis patients. Korean J Nephrol. 2008; 27:458–464.

8. Cordeiro AC, Qureshi AR, Stenvinkel P, et al. Abdominal fat deposition is associated with increased inflammation, protein-energy wasting and worse outcome in patients undergoing haemodialysis. Nephrol Dial Transplant. 2010; 25:562–568. PMID: 19762603.

9. Wu CC, Liou HH, Su PF, et al. Abdominal obesity is the most significant metabolic syndrome component predictive of cardiovascular events in chronic hemodialysis patients. Nephrol Dial Transplant. 2011; 26:3689–3695. PMID: 21357211.

10. Postorino M, Marino C, Tripepi G, Zoccali C. Abdominal obesity and all-cause and cardiovascular mortality in end-stage renal disease. J Am Coll Cardiol. 2009; 53:1265–1272. PMID: 19358939.

11. Su WS, Clase CM, Brimble KS, Margetts PJ, Wilkieson TJ, Gangji AS. Waist-to-Hip Ratio, Cardiovascular Outcomes, and Death in Peritoneal Dialysis Patients. Int J Nephrol. 2010; 2010:831243. PMID: 21188241.

12. Stolic R, Trajkovic G, Jovanovic A, et al. Association of metabolic changes with mortality of patients treated by peritoneal dialysis or hemodialysis. Ren Fail. 2010; 32:778–783. PMID: 20662689.

13. Lee MJ, Shin DH, Kim SJ, et al. Sagittal abdominal diameter is an independent predictor of all-cause and cardiovascular mortality in incident peritoneal dialysis patients. PLoS One. 2013; 8:e77082. PMID: 24167560.

14. Nolph KD, Moore HL, Prowant B, et al. Cross sectional assessment of weekly urea and creatinine clearances and indices of nutrition in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 1993; 13:178–183. PMID: 8369345.

15. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet. 2005; 366:1059–1062. PMID: 16182882.

16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18:499–502. PMID: 4337382.

17. Detsky AS, McLaughlin JR, Baker JP, et al. What is subjective global assessment of nutritional status? JPEN J Parenter Enteral Nutr. 1987; 11:8–13. PMID: 3820522.

18. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994; 47:1245–1251. PMID: 7722560.

19. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999; 341:1097–1105. PMID: 10511607.

20. Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006; 355:763–778. PMID: 16926275.

21. Hall WH, Ramachandran R, Narayan S, Jani AB, Vijayakumar S. An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer. 2004; 4:94. PMID: 15610554.

22. Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, et al. Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Am J Kidney Dis. 2005; 46:489–500. PMID: 16129211.

23. Kwon HS, Park YM, Lee HJ, et al. Prevalence and clinical characteristics of the metabolic syndrome in middleaged Korean adults. Korean J Intern Med. 2005; 20:310–316. PMID: 16491829.

24. Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med. 2008; 359:2105–2120. PMID: 19005195.

25. Price GM, Uauy R, Breeze E, Bulpitt CJ, Fletcher AE. Weight, shape, and mortality risk in older persons: elevated waist-hip ratio, not high body mass index, is associated with a greater risk of death. Am J Clin Nutr. 2006; 84:449–460. PMID: 16895897.

26. Carmienke S, Freitag MH, Pischon T, et al. General and abdominal obesity parameters and their combination in relation to mortality: a systematic review and meta-regression analysis. Eur J Clin Nutr. 2013; 67:573–585. PMID: 23511854.

27. Haslam DW, James WP. Obesity. Lancet. 2005; 366:1197–1209. PMID: 16198769.

28. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 2008; 9:367–377. PMID: 18401346.

29. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003; 63:793–808. PMID: 12631061.

30. Diaz-Buxo JA, Burgess WP. Is weight gain inevitable in most chronic peritoneal dialysis patients? Adv Perit Dial. 1992; 8:334–339. PMID: 1361818.

31. Navaneethan SD, Schold JD, Kirwan JP, et al. Metabolic syndrome, ESRD, and death in CKD. Clin J Am Soc Nephrol. 2013; 8:945–952. PMID: 23411425.

32. Szeto CC, Kwan BCH, Chow KM, et al. Metabolic syndrome in peritoneal dialysis patients: choice of diagnostic criteria and prognostic implications. Clin J Am Soc Nephrol. 2014; 9:779–787. PMID: 24458080.

33. Huang JW, Yang CY, Wu HY, et al. Metabolic syndrome and abdominal fat are associated with inflammation, but not with clinical outcomes, in peritoneal dialysis patients. Cardiovasc Diabetol. 2013; 12:86. PMID: 23758640.

34. Choi SJ, Kim EJ, Park MY, Kim JK, Hwang SD. Does body fat mass define survival in patients starting peritoneal dialysis? Perit Dial Int. 2014; 34:376–382. PMID: 23378474.

35. Nordfors L, Heimburger O, Lonnqvist F, et al. Fat tissue accumulation during peritoneal dialysis is associated with a polymorphism in a uncoupling protein 2. Kidney Int. 2000; 57:1713–1719. PMID: 10760107.

36. Wang X, Axelsson J, Nordfors L, et al. Changes in fat mass after initiation of maintenance dialysis is influenced by the uncoupling protein 2 exon 8 insertion/deletion polymorphism. Nephrol Dial Transplant. 2007; 22:196–202. PMID: 16982633.

37. Valdez R. A simple model-based index of abdominal adiposity. J Clin Epidemiol. 1991; 44:955–956. PMID: 1890438.

38. Pouliot MC, Despres JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994; 73:460–468. PMID: 8141087.

39. Parikh RM, Joshi SR, Pandia K. Index of central obesity is better than waist circumference in defining metabolic syndrome. Metab Syndr Relat Disord. 2009; 7:525–527. PMID: 19558273.

40. Iribarren C, Darbinian JA, Lo JC, Fireman BH, Go AS. Value of the sagittal abdominal diameter in coronary heart disease risk assessment: cohort study in a large, multiethnic population. Am J Epidemiol. 2006; 164:1150–1159. PMID: 17041127.

41. WHO. Waist Circumference and Waist-Hip Ratio: report of a WHO expert consultation. Geneva: World Health Organization (WHO);2008.

42. Seidell JC. Waist circumference and waist/hip ratio in relation to all-cause mortality, cancer and sleep apnea. Eur J Clin Nutr. 2010; 64:35–41. PMID: 19639001.

43. Cockcroft A, Gooch C, Ellinghouse C, Johnston M, Michie S. Evaluation of a programme of health measurements and advice among hospital staff. Occup Med (Lond). 1994; 44:70–76. PMID: 8032035.

44. Li PK, Kwan BC, Ko GT, Chow KM, Leung CB, Szeto CC. Treatment of metabolic syndrome in peritoneal dialysis patients. Perit Dial Int. 2009; 292:S149–S152. PMID: 19270205.

45. Bazanelli AP, Kamimura MA, Manfredi SR, Draibe SA, Cuppari L. Usefulness of waist circumference as a marker of abdominal adiposity in peritoneal dialysis: a cross-sectional and prospective analysis. Nephrol Dial Transplant. 2012; 27:790–795. PMID: 21948862.

46. Sanches FM, Avesani CM, Kamimura MA, et al. Waist circumference and visceral fat in CKD: a cross-sectional study. Am J Kidney Dis. 2008; 52:66–73. PMID: 18440683.

47. Churchill DN, Thorpe KE, Nolph KD, Keshaviah PR, Oreopoulos DG, Page D. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. The Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol. 1998; 9:1285–1292. PMID: 9644640.

48. Wang T, Heimburger O, Waniewski J, Bergstrom J, Lindholm B. Increased peritoneal permeability is associated with decreased fluid and small-solute removal and higher mortality in CAPD patients. Nephrol Dial Transplant. 1998; 13:1242–1249. PMID: 9623561.

49. Rumpsfeld M, McDonald SP, Johnson DW. Higher peritoneal transport status is associated with higher mortality and technique failure in the Australian and New Zealand peritoneal dialysis patient populations. J Am Soc Nephrol. 2006; 17:271–278. PMID: 16306167.

50. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol. 2002; 13:1307–1320. PMID: 11961019.

51. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program(NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486–2497. PMID: 11368702.